Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-ΚB pathway

Anti-Cancer Drugs

Volumn 25, Issue 10, 2014, Pages 1152-1164

  Li, Xiaoping ^a   Zhu, Weiliang ^a   Chen, Zhenzhu ^a   Luo, Luqiao ^a   Huang, Jie ^a   Zhang, Fan ^a   Li, Man ^a   Guo, Ying ^a   Guo, Linlang ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Cell growth; Chemoresistance; Fibroblast growth factor inducible 14; Nuclear factor b; Small cell lung cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL XL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; PROTEIN BCL X; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER STAGING; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; SMALL CELL LUNG CANCER; ANIMAL; BAGG ALBINO MOUSE; DRUG RESISTANCE; G1 PHASE CELL CYCLE CHECKPOINT; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MULTIDRUG RESISTANCE; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA;

EID: 84928116097     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000153     Document Type: Article

References (20)

1. Lally BE, Geiger AM, Urbanic JJ, Butler JM, Wentworth S, Perry MC, et al. Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer 2009; 64:226-231.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30.
3. Califano R, Abidin AZ, Peck R, Faivre-Finn C, Lorigan P. Management of small cell lung cancer: recent developments for optimal care. Drugs 2012; 72:471-490.
4. Lawson MH, Cummings NM, Rassl DM, Russell R, Brenton JD, Rintoul RC, Murphy G. Two novel determinants of etoposide resistance in small cell lung cancer. Cancer Res 2011; 71:4877-4887.
5. Rezonja R, Knez L, Cufer T, Mrhar A. Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions. Radiol Oncol 2013; 47:1-13.
6. Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SL, Peifley KA, et al. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 1999; 274:33166-33176.
7. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001; 15:837-846.
8. Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 2000; 156:1253-1261.
9. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002; 62:2890-2896.
10. Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 2003; 162:1313-1321.
11. Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappa B and correlate with poor patient outcome. Cancer Res 2006; 66:9535-9542.
12. Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, Brown SA, et al. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 2008; 6:725-734.
13. Watts GS, Tran NL, Berens ME, Bhattacharyya AK, Nelson MA, Montgomery EA, Sampliner RE. Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer 2007; 121:2132-2139.
14. Huang M, Narita S, Tsuchiya N, Ma Z, Numakura K, Obara T, et al. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome. Carcinogenesis 2011; 32:1589-1596.
15. Kwon OH, Park SJ, Kang TW, Kim M, Kim JH, Noh SM, et al. Elevated fibroblast growth factor-inducible 14 expression promotes gastric cancer growth via nuclear factor-kappaB and is associated with poor patient outcome. Cancer Lett 2012; 314:73-81.
16. Als AB, Dyrskjot L, von der MH, Koed K, Mansilla F, Toldbod HE, et al. Emmprin and survivin predict response and survival following cisplatincontaining chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007; 13:4407-4414.
17. Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, Hostetter G, et al. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol 2012; 181:111-120.
18. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005; 280:3483-3492.
19. Kaiser U, Schilli M, Haag U, Neumann K, Kreipe H, Kogan E, Havemann K. Expression of bcl-2-protein in small cell lung cancer. Lung Cancer 1996; 15:31-40.
20. Wang DG, Johnston CF, Sloan JM, Buchanan KD. Expression of bcl-2 in lung neuroendocrine tumors: comparison with p53. J Pathol 1998; 184:247-251.